Bengt I Eriksson Selected Research

Enoxaparin (Lovenox)

1/2015	Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials.
2/2014	Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
11/2012	Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
8/2012	Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
7/2012	Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.
6/2012	Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials.
4/2012	Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
4/2011	Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
3/2011	Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
12/2010	A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bengt I Eriksson Research Topics

Disease

41	Venous Thromboembolism 01/2015 - 01/2002
33	Hemorrhage 01/2019 - 03/2002
10	Venous Thrombosis (Deep-Vein Thrombosis) 01/2019 - 01/2002
8	Pulmonary Embolism 01/2019 - 04/2003
6	Thromboembolism 01/2011 - 02/2002
5	Rupture 06/2021 - 06/2006
4	Thrombosis (Thrombus) 09/2012 - 04/2003
3	Tibial Fractures (Fracture, Tibial) 06/2014 - 01/2013
3	Infections 01/2013 - 06/2012
3	Acute Coronary Syndrome 09/2012 - 09/2003
3	Thrombocytopenia (Thrombopenia) 12/2005 - 04/2003
1	Compartment Syndromes 01/2013
1	Pain (Aches) 01/2013
1	Overweight 11/2012
1	Surgical Wound Infection 06/2012
1	Wound Infection (Wound Infections) 04/2012
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2011
1	Body Weight (Weight, Body) 03/2011
1	Atrial Fibrillation 01/2011
1	Stroke (Strokes) 01/2011
1	Embolism (Embolus) 01/2011
1	Inflammation (Inflammations) 01/2004
1	Hypersensitivity (Allergy) 04/2003

Drug/Important Bio-Agent (IBA)

28	Enoxaparin (Lovenox)FDA LinkGeneric 01/2015 - 01/2002
13	Dabigatran FDA Link 08/2016 - 09/2007
13	Fondaparinux (Arixtra)FDA Link 06/2013 - 01/2002
11	RivaroxabanIBA 06/2013 - 11/2006
8	AnticoagulantsIBA 01/2019 - 01/2004
8	AntithrombinsIBA 06/2013 - 02/2002
8	melagatranIBA 01/2006 - 02/2002
7	ximelagatran (Exanta)IBA 01/2006 - 02/2002
5	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2019 - 09/2002
4	AntibodiesIBA 06/2021 - 04/2003
4	Factor Xa InhibitorsIBA 06/2013 - 01/2002
4	Thrombin FDA Link 01/2011 - 02/2002
3	apixabanIBA 06/2013 - 01/2006
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 08/2012 - 01/2006
3	Factor Xa (Coagulation Factor Xa)IBA 01/2011 - 05/2002
3	Heparin (Liquaemin)FDA LinkGeneric 12/2005 - 04/2003
3	Dalteparin (Dalteparin Sodium)FDA Link 07/2003 - 02/2002
2	Vitamin K FDA Link 06/2013 - 01/2004
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2013 - 06/2012
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 07/2012 - 01/2006
2	EnzymesIBA 04/2011 - 09/2009
2	Warfarin (Coumadin)FDA LinkGeneric 01/2011 - 01/2004
1	C.I. direct red 80IBA 06/2021
1	Collagen Type I (Type I Collagen)IBA 06/2021
1	Alcian BlueIBA 06/2021
1	Factor XIII (Coagulation Factor XIII)IBA 03/2016
1	Fibrinogen (Factor I)FDA Link 03/2016
1	Dynamin IIIBA 08/2015
1	Transcription Factor 3IBA 08/2015
1	vinyltriethoxysilane (VTES)IBA 02/2014
1	darexabanIBA 02/2014
1	Pharmaceutical PreparationsIBA 08/2012
1	ORALIT (ORS)IBA 07/2012
1	CreatinineIBA 03/2011
1	1- (1- (3- ((6- chloronaphthalen- 2- yl)sulfonyl)- 2- hydroxypropanoyl)piperidin- 4- yl)tetrahydropyrimidin- 2(1H)- oneIBA 12/2010
1	edoxabanIBA 09/2010
1	Complement System Proteins (Complement)IBA 06/2006
1	odiparcilIBA 01/2006
1	LY517717IBA 01/2006
1	GlycosaminoglycansIBA 01/2006
1	A-factor (Streptomyces)IBA 01/2006
1	Heparin Cofactor IIIBA 01/2006
1	Immunoglobulin G (IgG)IBA 12/2005
1	Platelet Factor 4IBA 12/2005
1	enoxaparin sodium FDA LinkGeneric 01/2005
1	desirudin (Iprivask)FDA Link 04/2003
1	HirudinsIBA 04/2003
1	lepirudin (Refludan)FDA Link 04/2003

Therapy/Procedure

11	Knee Replacement Arthroplasty (Total Knee Replacement) 03/2016 - 03/2002
10	Hip Replacement Arthroplasty (Total Hip Replacement) 01/2015 - 01/2005
9	Orthopedic Procedures 09/2012 - 01/2002
3	Therapeutics 07/2012 - 08/2004
2	Arthroplasty 03/2016 - 01/2006
2	External Fixators 01/2013 - 01/2013
2	Ilizarov Technique 01/2013 - 01/2013
2	Aftercare (After-Treatment) 09/2012 - 03/2007
1	Spinal Fusion (Spondylosyndesis) 03/2016
1	Intramedullary Fracture Fixation 06/2014
1	Debridement 01/2013
1	Fasciotomy 01/2013
1	Hand Hygiene 06/2012
1	Early Ambulation 11/2010
1	Intravenous Administration 01/2008
1	Oral Administration 01/2006
1	Injections 01/2006
1	Blood Transfusion (Blood Transfusions) 01/2005